BioMarin Pharma (BMRN) Reports PRIME Regulatory Support for BMN 270 Gene Therapy in Hemophilia A – StreetInsider.com
StreetInsider.com |
BioMarin Pharma (BMRN) Reports PRIME Regulatory Support for BMN 270 Gene Therapy in Hemophilia A
StreetInsider.com BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Medicines Agency (EMA) has granted access to its Priority Medicines (PRIME) regulatory initiative for the company's investigational gene therapy treatment for severe … |
